New Retina Radio by Eyetube

AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GA Nov 14, 2024

We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study assessing the safety and efficacy ONL1204 (ONL Therapeutics) delivered prior to RRD surgery. Did injecting ONL1204, which prevents Fas activation, lead to any postsurgical differences? Alex Melamud stops by to discuss the phase 2/3 SAGA study assessing the safety and efficacy of gildeuretinol (Alkeus Pharmaceuticals), an oral agent for the treatment of geographic atrophy. Can this drug succeed where other oral options in retina have failed?

AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD Nov 07, 2024

The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there any surprises in the data? Jeremiah Brown, MD, MS, sits down with New Retina Radio to review the philosophy behind the ELEVATUM study, discuss the study’s findings, and preview the next phases of the trial. And Eric Schneider, MD, joins the program to discuss the findings of a pivotal study assessing home OCT (Scanly, Notal Vision) in wet AMD patients. Is home OCT equivalent to in-office OCT when it comes to visualization? And do expert graders agree with an AI algorithm’s assessments of patient’s pathology?

AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement Oct 31, 2024

Are retina doctors seeing more retinal pathology following infection or vaccination? Or is there nothing to see here? Rahul Khurana, MD, joins us to discuss the findings of various health care database analyses seeking to clarify whether COVID infection or vaccination were linked to retinal manifestations. Was there a clear—or even an opaque—connection between the two? And Paul Hahn, MD, PhD, sits down with us to explain how inflation, new realities of reimbursement, and step therapy directives are playing out in retina clinics in the United States. Inflation-adjusted reimbursement is declining—but can anything be done about it? And is step therapy actually saving the system any cash?

GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition? Oct 28, 2024

We finally have two FDA-approved treatments for geographic atrophy (GA)—and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD, as he explores this question with Miguel Busquets, MD, and Esther Kim, MD. Further in the episode, they gameplan patient conversations centered around choosing a treatment, ask how heavily to weigh safety when selecting a complement inhibitor, and preview the GA pipeline.

New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in Endophthalmitis Prevention Oct 17, 2024

In this episode of the New Retina Radio Journal Club with VBS, Maura Di Nicola, MD; Sruthi Arepalli, MD, and Barton Blackorby, MD, discuss a recent study comparing endophthalmitis rates following anti-VEGF injections with pre-treatment using either 5% Povidone Iodine or 0.05% Chlorhexidine. They highlight how prefilled syringes can reduce the risk of endophthalmitis and explore the implications for clinical practice, including antiseptic protocols, patient sensitivities, and how to navigate conflicting study outcomes. Tune in for valuable insights that could influence your injection protocols.

Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR Oct 09, 2024

Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michael Klufas, MD, joined us for a discussion about another real-world study. This time, it was a retrospective multicenter outcomes analysis following multiple injections of high-dose aflibercept (Eylea HD, Regeneron) for treatment of wet AMD, DME, and DR. How did treatment-naïve patients fare compared with previously treated patients? And did treatment intervals improve? Stick with us to find out.

New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO Sep 17, 2024

What is the relationship between retinal artery occlusion (RAO) and death, stroke, or myocardial infarction? Moderator Katherine Talcott, MD, is joined by Kyle Kovacs, MD, and Phoebe Mellen, MD, to explore the latest contribution to the literature on this topic. After the break, they discuss how best to manage patients who present to the clinic with an RAO, review academic centers' model for rapidly assessing patients with RAOs, and strategize how best to perform work-ups for patients who present to the retinal clinic with an RAO weeks after reporting reduced vision.

ASRS ’24: C1q Inhibition and Metformin for AMD Sep 05, 2024

Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year—and what occurred when patients stopped receiving treatment. And later, Dimitra Skondra, MD, fills us in on the latest research regarding potential interactions between metformin and AMD development in non-diabetic patients. Does the future of care include metformin as prophylaxis? Stick with us to find out.

New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy Aug 29, 2024

Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinical decision-making, weigh the value of anatomic improvement that doesn't result in significant improvement in vision quality, and review their comfort with switching from legacy anti-VEGF agents to next-generation therapies.

ASRS ’24: PAVILION at 100 Weeks Aug 22, 2024

The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it came to treating diabetic retinopathy out to 100 weeks? Margaret Chang, MD, summarized the PAVILION study’s 2-year safety and efficacy findings regarding the PDS in patients with DR but no DME. Plus, Dr. Chang offers her opinions on what it will take for retina specialists to trust the PDS now that the next-generation model has been released. Hear what she has to say in this one-on-one interview.

ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings Aug 08, 2024

Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year’s meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of continuous dosing of pegcetacoplan (Syfovre, Apellis Pharmaceuticals). What did microperimetry findings reveal about long-term dosing with C3 inhibition? Join us in this episode to find out.

New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept in Protocol AC Jul 19, 2024

Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinically relevant, and explore other risk factors that may be worthy of further investigation.

From Trials to the Clinic: Using a Therapy With a Novel MOA to Treat Patients With DME Jul 11, 2024

One of the challenges associated with current anti-VEGF therapies for the management of DME is the need for frequent injections and the potential impact on adherence and vision outcomes. Join Dr. John Kitchens and Dr. Maria Berrocal as they share their experiences treating their DME patients using a therapy with a novel mechanism of action, and how those patient outcomes have influenced their extension decisions and treatment management approaches. This special episode of New Retina Radio, and its content, is supported by Genentech USA, Inc.

New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic Jun 27, 2024

What did a review of the AAO IRIS Registry reveal about the rates of retinal vein occlusion (RVO) during the COVID-19 pandemic? Moderator Katherine Talcott, MD, sits down with Phoebe Mellen, MD, and Kyle Kovacs, MD, to review the study's conclusion that RVO rates did not increase during the pandemic, discuss challenges about talking to patients seeking causality for an ocular phenomenon, and review the relative strengths and drawbacks of relying on the IRIS Registry.

A Treatment With a Novel MOA for Patients With nAMD and DME: Perspectives From the Real World Jun 20, 2024

Recent studies have proven the therapeutic viability of a different approach in treating retinal vascular diseases. Join Dr. John Kitchens, Dr. Margaret Chang, and Dr. David Chin Yee as they discuss their clinical experiences using a therapy with a novel mechanism of action in patients with nAMD and DME. And, learn how they approach managing patients with macular edema. This special episode of New Retina Radio, and its content, is supported by Genentech USA, Inc.

AMD and DME Applications in the Retina Practice: Real-world Data Jun 17, 2024

In the second episode of this 2-part series, moderator Paul Hahn, MD, PhD, and panelists Durga Borkar, MD, MMCi, and Ted Leng, MD, turn to the findings of FARETINA-AMD and FARETINA-DME, which rely on real-world outcomes as documented in the AAO IRIS Registry. What can retina specialists learn from these studies, and how might these studies' findings affect treatment decisions?

ARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depression Jun 05, 2024

Protocol AA might be complete—but analysis of its data is far from over. What did that study’s data tell us about the relationship between leakage and DR severity? Justis Ehlers, MD, breaks down what he and his team uncovered when examining ultra-widefield images from Protocol AA, and helps us understand how machine learning might be used in future retina clinics. And Lisa Faia, MD, explains what her claims database analysis uncovered about the overlap between GA diagnoses and rates of depression and anxiety. What new info do we have that can contextualize the value of GA care?

New Retina Radio Journal Club with VBS: New Retina Radio Journal Club with VBS: Is Buckling Effective for RRD in Patients at Risk for PVR? May 29, 2024

How do outcomes differ for RRD patients at risk of PVR following PPV alone or combined PPV/scleral buckling? Moderator David Xu, MD, hears from panelists Barton Blackorby, MD, and Prethy Rao, MD, MPH, about a recent peer-reviewed paper published in Ophthalmology Retina covering surgical outcomes of patients with RRD who were considered high risk for PVR and underwent either PPV alone or PPV/scleral buckling. After the break, the doctors discuss the specific mechanics of a PPV/scleral buckle that may lead to successful surgery and ask whether this paper helps us better understand risk factors for PVR.

ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE May 17, 2024

Could next-generation anti-VEGF agents such as faricimab (Vabysmo, Genentech/Roche) and high-dose aflibercept (Eylea HD, Regeneron) be dosed as infrequently as every 20 weeks without sacrificing efficacy? And even if there are data that suggest that finding, would anyone actually adopt an interval that long in wet AMD patients? Philip Storey, MD, fills us in on TENAYA and LUCERNE data that explored, in part, how many patients could theoretically reach a 20-week dosing interval with faricimab, and which baseline factors predicted whether patients were conducive to such a strategy. And Prof. Sobha Sivaprasad joins us to review findings from PULSAR. In particular, she focuses on data examining whether wet AMD patients could be dosed as long as every 24 weeks on high-dose aflibercept. This is part 1 of 2 of NRR's ARVO 2024 coverage.

GA Options in Clinical Therapy, Part 2: Real-world Cases in GA May 10, 2024

David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, return for the second episode in this podcast miniseries, in which they review a trio of real-world GA cases, explore what early responses to treatment look like, and ask how to address GA in the presence of wet AMD.

GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment Strategies May 10, 2024

Join David RP Almeida, MD, PhD, MBA; Lisa Faia, MD; and Chris Riemann, MD, as they assess which clinical and non-clinical characteristics drive their decision-making in patients with geographic atrophy (GA). After the break, Dr. Faia shares a real-world case from her clinic in which a patient who was lost to follow-up returns to consider treatment.

AMD and DME Applications in the Retina Practice: RCT Comparison May 08, 2024

What conclusions can be drawn from a cross-trial comparison of randomized clinical trials assessing the safety and efficacy of anti-VEGF agents used in the treatment of AMD and DME? Paul Hahn, MD, PhD, sits down with Durga Borkar, MD, MMCi, and Ted Leng, MD, to review a recent presentation by Dr. Leng on this topic, and to examine the clinical relevance of the study's findings.

The State of Biosimilars: Integration of Biosimilars into a Retina Practice Apr 25, 2024

Biosimilars in retina are here. How are practices integrating them into their clinics? And how do they navigate issues around payer policy, protocol changes, and ensuring continuity of care?

Moderator John Kitchens, MD, sits down with retina specialist Dave Brown, MD, and Kristin Yockus, the VP of Process Integrations at Retina Consultants of America, to answer these questions, and to preview how the coming increase in biosimilar options might play out in a real-world landscape.

New Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT Apr 19, 2024

How do endophthalmitis rates after intravitreal injection differ after using povidone-iodine compared with chlorhexidine? Moderator Sruthi Arepalli, MD, hears from panelists Vaidehi Dedania, MD, and Rebecca Soares, MD, MPH, about a recent peer-reviewed retrospective cohort study on this topic. After the break, the trio discuss how to manage patients who do not tolerate antiseptics, the benefits of visualizing antiseptics on the conjunctiva, and the specific practice patterns that work best in their clinics.

Successful Management of Vitreous Opacities Apr 02, 2024

Performing surgery for symptomatic vitreous opacities (SVO) was once verboten in retina medicine, but the field has seen a sea-change in mindset over the past decade. In this podcast, moderator John Kitchens, MD, is joined by Edwin H. Ryan, MD; Christina Y. Weng, MD, MBA; and Alison Bozung, OD, to explore why surgery for SVO has become more palatable and how this evolution in mindset is impacting patients' quality of life.

New Retina Radio Journal Club with VBS: Visual Outcomes Following Surgical RRD Repair Relative to Foveal Status and Time of Surgery Mar 28, 2024

Do the status of the fovea and/or the timing of surgery affect visual outcomes following RRD repair? Join New Retina Radio Journal Club host Lediana Goduni, MD, as she and panelists Matt Starr, MD, and Joshua Uhr, MD, dissect the findings of a recent paper exploring this question. After the break, the trio discusses tactics for overcoming challenges to real-world conditions when patients present at times when immediate surgery is not an option.

Treating Geographic Atrophy (GA) In Your Practice Mar 01, 2024

Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.

Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy Mar 01, 2024

Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.

The State of Biosimilars: How We Got Here and What It Means for Practice Feb 22, 2024

Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care?

Moderator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices.

This podcast is editorially independent, supported with advertising by Cimerli.

Cherchez la Femme Revisited Feb 16, 2024

The field of retina has made significant strides when it comes to diversity, equity, and inclusion since Julia A. Haller, MD, penned her inspirational 2015 JAMA Ophthalmology editorial, Cherchez la Femme. The ever-growing body of research on this topic stands as a testament to her commitment to understanding the gaps in diversity, particularly in terms of gender differences in leadership positions. Adrienne W. Scott, MD, and Steven Sanislo, MD, sit down with Dr. Haller to discuss the state of affairs in retina and just how far we have come—and how much is left to do.

How are we doing in terms of representation on the podium? How does diversity among retina specialists affect patient care? Why is it important to look for diversity when designing an ad board or conference agenda? What drove Dr. Haller to pursue a career in a traditionally male-dominated field? Check out this episode to hear what Dr. Haller has to say.

AAO ’23: Downward Trends in Reimbursement and ChatGPT in the Retina Clinic Dec 14, 2023

Reimbursements for vitreoretinal surgery have plummeted in the past decade. How dire is the situation? John Thompson, MD, updates listeners on the trends in Medicare reimbursement for a variety of vitreoretinal surgeries, imaging tests, and E&M visits—all of which have implications for the future of care and access to providers.

After the break, Raymond Iezzi, MD, discusses the risks and benefits to using large language models (LLMs) such as ChatGPT in a retina clinic. How will LLMs better serve providers and patients? And what drawbacks might create more confusion than needed? Check out this episode to learn more.

This Editorially independent content is supported with advertising.

New Retina Radio Journal Club: Intentional Suspension of Therapy in Wet AMD Dec 07, 2023

What are the consequences to intentional suspension of anti-VEGF therapy in wet AMD patients? Join moderator Sruthi Arepalli, MD, and panelists Rebecca Soares, MD, MPH, and Vaidehi Dedania, MD, as they explore the circumstances under which treatment might be suspended, examine a paper that described the consequences of treatment suspension, and review how they approach treatment suspension in their clinics.

AAO ’23: Real-World Faricimab Patterns and Improving GA Assessments Nov 30, 2023

The FARETINA-AMD study group assessed approximately 23,000 patients with wet AMD who had received at least one dose of faricimab (Vabysmo, Genentech/Roche). What have they found? Sophie Bakri, MD, summarizes the findings of an IRIS Registry review, which uncovered data about who has been dosed with faricimab, how frequently extended dosing intervals have been achieved, and whether real-world safety issues have cropped up.

And Karl Csaky, MD, PhD, offers a glimpse into the future of geographic atrophy care. Are any budding technologies better able to assess structure and function in GA patients? Keep it here to find out.

This Editorially independent content is supported with advertising.

New Retina Radio AAO Late-Breakers: PULSAR at 96 Weeks and Home OCT in Wet AMD Nov 22, 2023

They’re here: the 96-week data on aflibercept 8 mg (Eylea, Regeneron) in wet AMD. Jean-Francois Korobelnik, MD, PhD stops by to review the 96-week data from PULSAR. How closely did the 96-week results match those at 48 weeks? And how many patients could be extended to 16-, 20-, or even 24-week intervals?

Also, W. Lloyd Clark, MD, joins the show to discuss home-based OCT-guided management of wet AMD. How does home OCT fit into a patient’s life—and how might it shape the future of care? Listen here to find out.

New Retina Radio Journal Club: Prophylactic Laser for Lattice Degeneration in Fellow Eyes After RRD Repair Nov 21, 2023

How effective is prophylactic laser for preventing fellow eye RT/RRD in patients with lattice degeneration who underwent uncomplicated primary RRD repair? NRR Journal Club with VBS moderator David Xu, MD, and panelists Prethy Rao, MD, and Barton Blackorby, MD, summarize a recent study that explored rates of fellow eye RT/RRD in this patient population by comparing cohorts who did and did not receive prophylactic laser in their fellow eye. The group dives deeper into the data to see how PVD presence, myopia severity, and phakic status affected rates of fellow eye RT/RRD, and asks whether and how these data can be applied to a modern surgical strategy.

New Retina Radio AAO Late-Breakers: ALTITUDE and DIAMOND Nov 13, 2023

RGX-314 (Regenxbio) could be a one-time gene therapy that addresses diabetic retinopathy. How did it perform in the phase 2 ALTITUDE study? Mark Barakat, MD, shares 1-year safety and efficacy findings from the first two dosing levels of RGX-314 in patients with DR. What are the data? And what’s coming next?

And Hani Salehi-Had, MD, joins the show to tell us about the findings in the DIAMOND study, a clinical trial assessing the safety and efficacy of OCS-01 (Oculis), an eye drop designed to treat DME. What did he and his study colleagues find? Keep it here to find out.

New Retina Radio Journal Club: Are Postpartum Retinal Detachment Rates Linked to Method of Delivery? Oct 26, 2023

Do patients with a history of retinal detachment (RD) experience higher rates of postpartum RD based on whether they delivered vaginally or via caesarean section? Join NRR Journal Club with VBS moderator Lediana Goduni, MD, and panelists Matt Starr, MD, and Joshua Uhr, MD, as they recap a new paper on this topic. After the break, the group reviews the limitations of this 30-year retrospective analysis, question whether RDs observed in the study were even linked to delivery irrespective of method, and discuss whether ophthalmic history should have any bearing on delivery recommendations.

Chronic Postoperative Inflammation: Patient Scenarios Oct 05, 2023

How do retina specialists manage real-world patients with chronic postoperative inflammation? Host John Kitchens, MD, poses various scenarios to panelists Brian Do, MD, and Katherine Talcott, MD, to better understand their approaches to controlling postoperative inflammation in a variety of patients. After the break, the group focuses on the real-world use of long-term steroid-eluting options in this patient population.

This editorially independent episode is supported by advertising from Alimera Sciences, Inc.

New Retina Radio Journal Club: Cost Evaluation in DME Therapy Sep 28, 2023

Researchers performed a cost analysis of the DRCR Retina Network’s Protocol AC study comparing on-label and off-label anti-VEGF use in DME therapy. What did they determine? Moderator Priya Vakharia, MD, invites panelists Sruthi Arepalli, MD, and Vaidehi Dedania, MD, to review the details of this economic examination. After the break, they explore how studies such as this one affect policy and probe the relevance of these findings in a world with longer-acting therapeutic agents.

How Imaging Helps Clinics Integrate New Therapies in GA Sep 25, 2023

How do retina specialists introduce new therapies to patients, and how does thoughtful use of imaging help providers integrate new treatments into their clinics? Moderator Aleksandra Rachitskaya, MD, joins panelists Mrinali Gupta, MD, and Katherine Talcott, MD, to review how innovations in imaging software have helped onboard GA therapies in real-world clinics. This episode is sponsored by ZEISS.

Luminaries in Retina: Kirk Packo, MD, FACS (Part 2) Sep 22, 2023

In part 2 of this special podcast interview with John W. Kitchens, MD, and Kirk Packo, MD, FACS, they dive into Dr. Packo's involvement in the creation of AAO subspecialty day, his passion for honoring the history of retina, and his assistance in advocating for vitreoretinal surgery improvements.

This podcast is editorially independent.

Luminaries in Retina: Kirk Packo, MD, FACS (Part 1) Sep 22, 2023

John W. Kitchens, MD, interviews Kirk Packo, MD, FACS, around his triumphant career and his decision to retire from practicing medicine following an unexpected diagnosis. In part 1 of 2, Dr. Packo describes his early career goals, his experience with residency matching, his background in acting and directing, and his passion for educating.

This podcast is editorially independent.

Chronic Postoperative Inflammation: Steroids’ Role in Treatment Sep 21, 2023

How do retina specialists manage patients who present with postoperative inflammation following cataract surgery? Host John Kitchens, MD, and panelists Vaidehi Dedania, MD, and David Eichenbaum, MD, explore the role steroids play in inflammation reduction and examine whether and why extended-release steroids are needed. After the break, Dr. Kitchens quizzes the panelists on their use of specific steroids in postoperative inflammation patients.

This editorially independent episode is supported by advertising from Alimera Sciences, Inc.

New Retina Radio Journal Club: Meta-analysis of PPV for Diabetic TRD Sep 07, 2023

What did a meta-analysis of studies assessing the safety and efficacy of vitrectomy for diabetic tractional retinal detachment (TRD) find when it comes to the rate of retinal reattachment and final visual acuity? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, outline the top-line findings of this meta-analysis, explore why the study's conclusions brush against conventional understandings of diabetic TRD outcomes following surgery, and ask whether the success bias of published studies undercut the real-world value of meta-analyses.

ASRS ’23: Pegcetacoplan Extension Study, and Comparison of Pegcetacoplan and Avacincaptad Pegol Sep 01, 2023

New Retina Radio was at ASRS 2023 to cover the stories you may have missed.

How did patients fare in the GALE extension study, which assessed the safety and efficacy of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) for geographic atrophy? Nathan C. Steinle, MD, shares the results of the first 6 months of GALE, in which patients who received treatment for 24 months in DERBY/OAKS continued with therapy—and in which patients who had received sham treatment for 24 months were switched over to treatment.

Paul Hahn, MD, PhD, joined us in our mobile studio in Seattle to share data from a matching-adjusted indirect comparison of pegcetacoplan and avacincaptad pegol (Izervay, Iveric Bio). What did he and his team find?

This is episode 2 of 2 covering the 2023 ASRS Annual Meeting. Go back in your feed to listen to episode 1.

Chronic Postoperative Inflammation: Initial Encounters Aug 25, 2023

What are the first steps retina specialists should take when a patient presents with postoperative inflammation? Host John Kitchens, MD, is joined by panelists Lisa Faia, MD, and Daniel Kiernan, MD, to debut the NRR miniseries "New Approaches to Chronic Postoperative Inflammation." They review which initial evaluation steps are most useful, discuss the wide range of preventive and treatment strategies, and offer pearls to clinicians who are managing postoperative inflammation.

This editorially independent episode is supported by advertising from Alimera Sciences, Inc.

Imaging Geographic Atrophy: OCT, FAF, NIR, and OCTA Aug 22, 2023

As we enter the therapeutic era of geographic atrophy, imaging the disease is more important than ever. How are retina specialists navigating this new clinical dynamic? Moderator Rishi P. Singh, MD, is joined by Roger A. Goldberg, MD, MBA; Mrinali Gupta, MD; and Katherine Talcott, MD, as they examine which imaging modalities are best suited for busy clinics, discuss how software can facilitate longitudinal imaging tracking, and review which imaging reports are most conducive to patient education. This episode is sponsored by ZEISS.

ASRS ’23: Missed Injections for AMD/DME/RVO and Anatomic Response to Vabysmo in Wet AMD Aug 11, 2023

New Retina Radio was at ASRS 2023 to cover the stories you may have missed.

How often do patients return to the clinic on time for anti-VEGF injections? Christina Y. Weng, MD, MBA, and her team explored how often patients missed scheduled appointments, by how much, and whether missing appointments affected patient outcomes.

And Nikolas JS London, MD, joined us in our mobile studio in Seattle to tell us about anatomic outcomes in wet AMD patients after faricimab (Vabysmo, Genentech/Roche) treatment.

This is episode 1 of 2 covering the 2023 ASRS Annual Meeting. Keep an eye on your feed for episode 2.

New Retina Radio Journal Club: Is Software on Home OCT as Good as Human Graders? Jul 20, 2023

How often did human graders agree with software designed to detect and quantify retinal fluid in wet AMD patients using a home OCT prototype? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to examine how reliable such software was in a prospective observational study. After the break, the group speculates how these new data may affect retina doctors' comfort with home OCT and asks what is the minimum viable image quality required to trust home OCT imaging.

New Retina Radio Journal Club: Wet AMD: Fluid-free Visits' Association with Anatomic and Visual Outcomes May 25, 2023

Were fluid-free visits correlated with outcomes in the HAWK/HARRIER studies? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, summarize data from a study examining this question, review what it means to be "free of fluid," and discuss how these data fit into the overall conversation about fluid toleration in wet AMD.

New Retina Radio ARVO Coverage: DME Update: 8-mg Aflibercept data and Faricimab TAE in Phase 3 May 18, 2023

Is a solution to extending duration with aflibercept (Eylea, Regeneron) in DME patients an 8-mg dose rather than the typical 2-mg dose? Diana Do, MD, joined us to review data from the PHOTON study, which assessed the safety and efficacy of high-dose aflibercept in DME patients.

And we hear from Jennifer Lim, MD, who summarized data on extending treatment intervals in the phase 3 YOSEMITE and RHINE studies. Could a significant number of DME patients make it to 12—or even 16—weeks before needing another faricimab (Vabysmo, Genentech/Roche) dose?

New Retina Radio ARVO Coverage: Faricimab in Wet AMD: Real-world and Phase 3 Data May 11, 2023

How are doctors using faricimab (Vabysmo, Genentech/Roche) in real-world settings? The IRIS Registry has a few answers. We sat down with Durga Borkar, MD, MMCi, to hear what researchers in the FARETINA-AMD study group found regarding dynamics related to faricimab’s use in wet AMD patients since its approval in January of last year.

We also interviewed Varun Chaudhary, MD, to learn specifically about faricimab treat-and-extend regimens in wet AMD patients who were enrolled in TENAYA and LUCERNE. How many patients achieved treatment intervals of 12 or 16 weeks?

Treating GA In Your Clinic May 03, 2023

After years of failed clinical trials, we finally have an approved therapy for geographic atrophy, and more are hopefully on the way. Allen C. Ho, MD, and Robert L. Avery, MD, sit down with Eleonora M. Lad, MD, PhD; Jeffrey S. Heier, MD; and Dilsher Dhoot, MD, to discussthe introduction of geographic atrophy therapies into the retina clinic.

New Retina Radio Journal Club: AMD and Depression Risk Apr 20, 2023

What did an analysis of the Korean National Health Insurance Service database reveal about the link between age-related macular degeneration and depression risk? Moderator Sabin Dang, MD, is joined by panelists Lediana Goduni, MD, and Prethy Rao, MD, MPH, to summarize the study's findings. After the break, the discussion turns to whether depression screening should (or could) occur in retinal clinics, and how optimistic framing of a diagnosis may make a difference in the lives of patients.

New Retina Radio Journal Club: Duration of Macular Detachment and Final Visual Prognosis Mar 28, 2023

What does an analysis of the Japan-Retinal Detachment Registry reveal about the relationship between duration of macular detachment and visual prognosis? Moderator Priya Vakharia, MD, invites panelists Sruthi Arepalli, MD, and Vaidehi Dedania, MD, to explore the design and findings of a recent paper by Miyake et al on this topic. After the break, they discuss the clinical and medico-legal implications of the paper’s findings.

The Utility of OCTA in the Clinic Mar 27, 2023

Cynthia A. Toth, MD, and Amani A. Fawzi, MD, sit down with experts Philip J. Rosenfeld, MD, PhD; SriniVas Sadda, MD; and Nadia K. Waheed, MD, MPH, to discuss the value of OCT angiography in the retina clinic. From assessing macular neovascularization to tracking treatment effect in patients with plaque choroidal retinopathies, this imaging modality can augment current tools—and even replace them, at times. Hear their pearls, tips, and tricks for integrating OCT angiography into your clinical routine.

The Era of Geographic Atrophy Treatment Begins Feb 23, 2023

The FDA approval of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) is a historic moment for the field of retina, finally providing a treatment option for patients with geographic atrophy. Allen C. Ho, MD, and Robert L. Avery, MD, share their initial reactions to the approval and discuss the potential effect on patient care and clinical practice.

Inclusion Pearls and Pitfalls For Retina Specialists Feb 13, 2023

Diversity and inclusion in medical practice is essential, and while retina specialists always have their patients’ and colleagues’ best interests at heart, sometimes that message can get lost in translation, especially when it comes to LGBTQ+ sensitivities. Vivienne S. Hau, MD, PhD, and Basil K. Williams Jr, MD, sat down with four experts—Jessica Weinstein, MD; Roberto Diaz-Rohena, MD; Steven Sanislo, MD; and Brandon Johnson, MD—to discuss ways to foster workplace diversity and inclusion for LGBTQ+ patients and physicians.

Tips for Mastering Secondary IOLs Dec 29, 2022

No two secondary IOL procedures are the same, and each case requires your full attention. What is your favorite technique? How are you protecting the haptics and avoiding hypotony? Hear from four of the top retina surgeons on their preferred approaches and how they avoid common surgical pitfalls.

A conversation with Christina Y. Weng, MD, MBA; Ashkan M. Abbey, MD; María H. Berrocal, MD; and Omesh P. Gupta, MD, MBA

New Retina Radio Journal Club: Profiling Punctate Inner Choroidopathy-like Reactions Dec 15, 2022

Punctate inner choroidopathy-like, or PIC-like, reactions are rare, and they sometimesl confound retina specialists. New Retina Radio Journal Club with VBS panelists Kyle Kovacs, MD, and Priya Vakharia, MD, join moderator Yasha Modi, MD, to review a retrospective observational study of patients with PIC-like presentations in unrelated chorioretinal disorders.

AAO '22: Biosimilars’ Practice Implications and Year 2 of YOSEMITE/RHINE Dec 09, 2022

Two biosimilars have been approved by the US FDA, and more are going to receive approval soon. With this level of disruption in US retina practice, what do you need know? George Williams, MD, the Senior Secretary for Advocacy at the AAO, joined us for preview on what practice might look like now that biosimilars are a fact of life. Also, Caroline Baumal, MD, sat down with us to discuss the YOSEMITE and RHINE studies, which released 2-year results. How did patients receiving faricimab (Vabysmo, Genentech/Roche) respond during their second year of treatment?

Innovations in Retinal Imaging Dec 05, 2022

John Kitchens, MD, invites Aleksandra Rachitskaya, MD, and Jonathan Russell, MD, PhD, to discuss the use of imaging technology in the retina clinic. The surgeons discuss cases in which they share approaches to imaging to evaluate wet age-related macular degeneration, retinal detachments, and more. They explain the value of OCT, ultra-widefield imaging, and fluorescein angiography, and comment on the use of change analysis with the Cirrus 6000 and Retina Workplace. Finally, the trio provides insights into the potential future of imaging technology. This podcast is sponsored by ZEISS.

AAO '22 Late-Breaking Talks: Gene Therapies for GA and XLRP Dec 01, 2022

We know about long-term intravitreal injections that might slow the progression of geographic atrophy (GA). But could a gene therapy in the pipeline require fewer treatments and still yield results? Jeffrey Heier, MD, summarized an AAO presentation on the phase 1 data of JNJ-1887 (Janssen), a potential gene therapy for GA. Was it safe—and were there signs of efficacy? Michel Michaelides, BSc, MB,, BS MD(Res), FRCOphth, joined us to speak about a gene therapy targeting x-linked retinitis pigmentosa. With a phase 3 study for the drug AAV5-RPGR (Jannsen/MeiraGTx) already underway, what can we learn from earlier trial results?

New Retina Radio Journal Club: Biosimilars in Retina: A Pair of Phase 3 Papers Nov 17, 2022

Two biosimilars have been approved for retinal indications. What conclusions were drawn from the phase 3 studies that preceded their approval? Yasha Modi, MD, is joined by Kyle Kovacs, MD, and Priya Vakharia, MD, to review the ins and outs of biosimilarity, discuss the findings of two recent papers, and consider how use of biosimilars might affect future clinical practice in the United States.

AAO '22: Biomarkers and AI in the OR Nov 10, 2022

Identifying systemic biomarkers indicating risk for age-related macular degeneration would be a game-changer. But how can we find those biomarkers? We spoke with Joan Miller, MD, whose work with the Harvard Retina Metabolomics Program focuses on identifying specific metabolites that might be useful in real-world practice. Also, Yannek Leiderman, MD, PhD, stopped by to fill us in on the state of artificial intelligence (AI) in the OR. How far away are surgeons from interacting in real time with AI?

AAO '22 Late-Breaking Talks: Biosimilar Phase 3 Data and TRUCKEE Update Nov 03, 2022

Phase 3 data evaluating the biosimilarity of a new biosimilar (Xlucane, Xbrane Biopharma) referencing ranibizumab (Lucentis, Genentech) has been completed. What were the results? Anat Loewenstein, MD, joined New Retina Radio to walk us through the results of the XPLORE study. And Ramanath Bhandari, MD, summarized his presentation on the TRUCKEE study, a real-world evaluation of the performance of faricimab (Vabysmo, Genentech/Roche). What do the most recent updates tell us about practice patterns and patient response?

AAO '22: GATHER2 Study Results Oct 25, 2022

Researchers in the second pivotal study evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio) for the treatment of geographic atrophy have released 1-year results. New Retina Radio spoke with Arshad Khanani, MD, MS, about the GATHER2 study findings. How did the study results compare to the GATHER1 conclusions—and might the company move forward with a regulatory filing?

New Retina Radio Journal Club: Latest Literature in Stickler Syndrome and GRTs Oct 13, 2022

What is the effect of laser prophylaxis in patients with Stickler Syndrome, and just how effective are buckles in patients with GRT detachments? Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to review two recent contributions to the literature, during which they probe the papers' findings and explore their limitations.

New Retina Radio Journal Club: Updates in ROP Sep 30, 2022

What changed in the most recent iteration of the International Classification of Retinopathy of Prematurity? And what do new data tell us about how ROP patients fare in adulthood? To find out, Yoshi Yonekawa, MD, PhD, is joined by Peter Campbell, MD; Karen Jeng-Miller, MD; and Prethy Rao, MD, to break down the latest literature, examine the papers' limitations, and offer pearls for surgical management of adults with history of ROP.

ASRS Meeting Coverage Day 3: DR Biomarkers and Gene Tx for Achromatopsia Sep 15, 2022

Can a quantitative analysis of OCT images detect early diabetic retinopathy in patients without symptoms? New Retina Radio spoke with Jennifer Lim, MD, whose research team sought to learn whether imaging analyses of photoreceptor length and reflectivity parameters could serve as a biomarker for disease detection.

We also sat down with Lejla Vajzovic, MD, who shared data on a pair of phase 1 studies assessing the safety and efficacy of two gene therapies for achromatopsia. One of those two drugs will be going on for further study. Which one? Stick with us to find out.

New Retina Radio Journal Club: Multifocal, Indolent, Nonprogressive Choroidal Lesions Aug 25, 2022

Retina specialists may wish to turn to the literature to learn more about multifocal, indolent, nonprogressive choroidal lesions. Let the New Retina Radio Journal Club with VBS help you out. Moderator Kyle Kovacs, MD, is joined by Cynthia Qian, MD, and David Xu, MD, to review two recent papers on this atypical presentation.

ASRS Meeting Coverage: Day 2 Aug 04, 2022

Was treat-and-extend faricimab (Vabysmo, Genentech) an effective means of controlling DME in the YOSEMITE and RHINE studies? New Retina Radio spoke with John Kitchens, MD, whose ASRS presentation reviewed results from a pair of phase 3 studies that assessed, in part, 12- and 16-week dosing intervals of faricimab in patients with DME.

Also joining us is Michael Allingham, MD, PhD. He shared results from the phase 2b ZETA-1 study, which examined the safety and efficacy of APX3330 (Ocuphire Pharma), an oral medication for DR. What promise might this treatment hold? Tune in to learn more.

This editorially independent podcast is supported with advertising.

ASRS Meeting Coverage: Day 1 Jul 28, 2022

Treat-and-extend regimens has been used for thousands of wet AMD patients. How does brolucizumab (Beovu, Novartis) stack up when compared with aflibercept (Eylea, Regeneron) in a matched treat-and-extend study? New Retina Radio spoke with Carl Regillo, MD, a member of the TALON study group, which sought to find out if brolucizumab was superior to aflibercept for extending treatment intervals in wet AMD patients.

We also spoke with Carl Danzig, MD, whose work on the TRUCKEE study illuminates real-world treatment dynamics when it comes to the use of faricimab (Vabysmo, Genentech) in wet AMD treatment. How are patients responding in the real world?

New Retina Radio Journal Club: Recurrent RRD Management Jul 14, 2022

How might two recent contributions to the literature deepen our understanding of recurrent rhegmatogenous retinal detachment (RRD)? To find out, moderator Kyle Kovacs, MD, is joined by panelists Cynthia Qian, MD, and David Xu, MD, to review a pair of papers on the topic. After the break, the group tackles tamponade selection and use of scleral buckles in patients with RRD, and discusses tactics for bringing a patient back to the OR if RRD recurs.

This editorially independent podcast is supported with advertising.

The Life and Career of Steve Charles, MD, FACS, FICS, FASRS Jun 30, 2022

In this episode, John W. Kitchens, MD, speaks with Steve Charles, MD, FACS, FICS, FASRS, a vitreoretinal surgeon and founder of the Charles Retina Institute in Germantown, Tennessee, as well as clinical professor of ophthalmology at the University of Tennessee in Memphis. Known to many as the architect behind the ACCURUS and CONSTELLATION from Alcon, his career is wildly impressive, but Dr. Kitchens finds his life and career history even more fascinating.

This podcast is editorially independent.

New Retina Radio Journal Club: Pentosan Polysulfate Maculopathy Jun 23, 2022

What are the latest findings regarding pentosan poloysulfate maculopathy (PPM)? Moderator Basil Williams, MD, invites panelists Karen Jeng-Miller, MD, MPH; M. Ali Khan, MD; and Katherine Talcott, MD, to review two recent publications seeking to better characterize the condition After the break, the discussion turns to the utility of imaging modalities in PPM management and an exploration into hospital-based policies that might lead to earlier detection of PPM in patients undergoing a new course of pentosan polysulfate sodium therapy.

ARVO Meeting Coverage Day 3: CANDELA and ARCHWAY Data Jun 09, 2022

Could an 8-mg dose intensify the therapeutic effect of aflibercept (Eylea, Regeneron) in patients with wet AMD? The phase 2 CANDELA study sought to explore the safety and efficacy of high-dose aflibercept in this patient population. What did Dave Brown, MD, and his research colleagues observe?

And 96-week data from ARCHWAY are in. Did the complete study, which reached its primary endpoint after 40 weeks, reveal new data that could affect clinical decision-making when it comes to real-world use of the Port Delivery System with Ranibizumab (Susvimo, Genentech)? Hear our interview with Robert Mittra, MD, to find out.

This editorially independent podcast is supported with advertising.

ARVO Meeting Coverage Day 2: Pipeline Therapies in GA Jun 02, 2022

Could RPE cell replacement therapy be the future of GA treatments? Retina Today’s Chief Medical Editor Allen C. Ho, MD, joined us to discuss observations from a phase 1/2a study evaluating the safety and efficacy of OpRegen (Lineage Cell Therapeutics), a suspension of allogenic RPE cells implanted in the subretinal space. How well was this therapy tolerated, and were there any signs of vision improvement?

Elsewhere in the GA pipeline, researchers are exploring whether the gene therapy GT005 (Gyroscope Therapeutics) might be a safe and effective one-time treatment for GA via upregulation of complement factor I. How does complement factor I affect the course of GA, and what are the latest data from a phase 1/2 study? Check out this episode to hear on conversation on that topic with Jared Nielsen, MD, MBA.

This podcast is editorially independent, supported with advertising.

ARVO Meeting Coverage Day 1: LIGHTSITE III and DERBY/OAKS at 18 Months May 26, 2022

Could photobiomodulation soon be a therapeutic option for patients with dry AMD? Researchers in the LIGHTSITE III study are working toward finding out. We spoke with Marion Munk, MD, PhD, about the details from a study that evaluated the Valeda Light Delivery System (LumiThera) in patients with dry AMD. Were patients able to safely realize any improvement to visual function?

And we checked in with Roger Goldberg, MD, MBA, who detailed the 18-month findings of the DERBY and OAKS studies, a pair of phase 3 clinical trials evaluating the safety and efficacy of pegcetacoplan (APL-2, Apellis Pharmaceuticals) in patients with geographic atrophy. The studies’ primary endpoint was at 1 year. What did they find after an additional 6 months? Stick here to find out.

New Treatment Options and Considerations for AMD May 19, 2022

Anti-VEGF therapy has been a game changer for patients with AMD; now, the treatment toolbox is getting an overhaul with two new approvals and, hopefully, more on the way. Allen C. Ho, MD, sat down with Robyn Guymer AM, MBBS, PhD, FRANZCO, FAHMS; Charles C. Wykoff, MD, PhD; and Diana V. Do, MD, to discuss how these new treatments are going to change clinical practice and how to educate patients on the pros and cons of each option.

New Retina Radio Journal Club: Trends in Retina Reimbursement May 12, 2022

How has reimbursement for common vitreoretinal procedures changed from 2011 to 2020? To find out, moderator Eric Nudleman, MD, PhD, hears from panelists John Miller, MD; Thanos Papakostas, MD; and Priya Vakharia, MD, as they discuss a recent piece on the topic published in the journal Ophthalmology. After reviewing the findings, the panel discusses the implications for reduced reimbursement in an era of improved efficiency and asks whether future innovation will allow patients to receive the same level of care even as reimbursement declines.

New Retina Radio Journal Club: Diversity in Clinical Trials Apr 21, 2022

Do the demographics of patients enrolled in clinical trials accurately reflect the patient populations their drugs intend to treat? Moderator Basil Williams, MD, is joined by panelists Karen Jeng-Miller, MD, MPH; M. Ali Khan, MD, and Katherine Talcott, MD, to summarize a pair of papers exploring this topic. After summarizing the papers' findings, the group reviews a phase 4 trial seeking to enroll underrepresented patients and asks which barriers to enrollment may be linked to shortcomings in demographic diversity.

New Retina Radio Journal Club: PPV vs PnR for RRD Mar 31, 2022

Pars plana vitrectomy (PPV) and pneumatic retinopexy (PnR) are both commonly employed to repair rhegmatogenous retinal detachment (RRD). What does the literature have to say about the safety and outcomes of these two procedures? Moderator Eric Nudleman, MD, PhD, asks panelists John Miller, MD; Thanos Papakostas, MD; and Priya Vakharia, MD, to break down the PIVOT and ALIGN studies, both of which were recently published in the journal Ophthalmology Retina. What were these studies’ findings—and how accurately do they reflect clinical experience?

Art of Drug Choice: Treating New Wet AMD Patients Mar 24, 2022

Have innovations in therapy actually led to a paradigm shift when it comes to encountering patients with newly diagnosed wet AMD? In the season finale of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by panelists Lejla Vajzovic, MD, and Joseph M. Coney, MD, to review strategies for treating new wet AMD patients, to discuss where new technologies fit into a treatment algorithm, and to examine the best time to switch patients to a new therapeutic option. After the break, Dr. Khanani updates the panel on a patient case shared in previous seasons of this series, which involves a patient with a 12-year treatment history who experienced significant vision loss following a change in therapy. How did Dr. Khanani manage the case—and what happened after inflammation was brought under control?

This editorially independent podcast is supported with advertising.

Art of Drug Choice: Who Is Best Suited for Extended-duration Therapy? Mar 17, 2022

How do retina specialists decide which wet AMD patients are best suited for extended duration therapy and which patients should continue with more traditional intervention? In the second episode of this season of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, asks Lejla Vajzovic, MD, and Joseph M. Coney, MD, about which factors they weigh most heavily when determining if a patient could be a good candidate for a change in treatment strategy, and discuss how gene therapy may play a role in wet AMD treatment. After the break, Dr. Vajzovic reviews the case of a patient who has undergone treatment with three different anti-VEGF agents. Why and when did she switch this patient to a different therapy?

This editorially independent podcast is supported with advertising.

Art of Drug Choice: The Latest Advances in Wet AMD Therapy Mar 03, 2022

How have the most recent advances in wet AMD therapy changed the treatment landscape for clinicians? In this debut episode of the third season of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by Lejla Vajzovic, MD, and Joseph M. Coney, MD, for a discussion about choosing patients who are best suited for the recently approved therapies, and for a preview of how biosimilars could affect treatment decisions. After the break, Dr. Coney shares the case of a patient whose need to extend treatment intervals was addressed by switching to a new anti-VEGF agent.

This editorially independent podcast is supported with advertising.

Anti-VEGF, A Biography: Part 3 Feb 24, 2022

This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again. Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography. This editorially independent podcast is supported with advertising.

Anti-VEGF, A Biography: Part 2 Feb 17, 2022

New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD. This editorially independent podcast is supported with advertising.

Exploring the clinical development program for an innovative, continuous delivery treatment for nAMD Feb 11, 2022

Recently, the first refillable, intraocular device that enables continuous delivery of therapy was FDA approved for nAMD. John Kitchens, MD sits down with one of the investigators, Dante Pieramici, MD, to learn more about his experiences with the clinical development program and this innovative drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

Tackling PVR in the OR Feb 03, 2022

In this roundtable moderated by Allen C. Ho, MD, and Robert L. Avery, MD, experts discuss the frustration of postoperative proliferative vitreoretinopathy and strategies to minimize its incidence in the clinic.

Panelists include Dean Eliott, MD; Avni P. Finn, MD, MBA; Ajay Kuriyan, MD, MS; and M. Ali Khan, MD. This podcast is editorially independent.

Anti-VEGF, A Biography: Part 1 Jan 27, 2022

Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD. This editorially independent podcast is supported with advertising.

Perspectives on an innovative drug delivery system for nAMD: From training to initial experiences Jan 18, 2022

Innovation often drives surgeons to adopt new techniques and surgical approaches. Join John Kitchens, MD, Carl Awh, MD, and Aleksandra Rachitskaya, MD as they discuss their experiences with a new refillable, intraocular device that enables continuous delivery of therapy for patients with nAMD. Listen as they provide their insights on learning the implant and refill- exchange procedures as well as their perspectives on the training program for the device. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

Matching Patients to Therapy in Wet AMD: Lifestyle Factors That Guide Treatment Jan 04, 2022

In the culmination of this case-based series discussing who is best suited for which types of wet AMD therapy, John Kitchens, MD, invites Murtaza Adam, MD, and Aleksandra Rachitskaya, MD, to the program to showcase two real-world patient files. After they are done with case discussions, Drs. Adam, Kitchens, and Rachitskaya examine how patient lifestyle details may affect treatment strategies.

This editorially independent podcast is supported with advertising.

Matching Patients to Therapy in Wet AMD: Deciding Who Is Best Suited for Long-Duration Treatments Dec 22, 2021

In the second installment of this ongoing series covering wet AMD, Lisa Faia, MD, and Sumit Sharma, MD, submit to host John Kitchens, MD, a set of real-world patient cases in which treatment challenges necessitated a change in therapy. After revealing which treatment option is best suited for their respective patients, Drs. Faia and Sharma parse which patient types are eligible for long-duration treatment and which types are better matched for more traditional approaches.

This editorially independent podcast is supported with advertising.

AAO 2021: Updates in Uveitis and Trauma Dec 17, 2021

Changes to the uveitis treatment landscape after years of stagnation warrant a reset on what is approved, what the latest data are, and which developments are in the pipeline. Glenn Jaffe, MD, summarized his state of the union on uveitis therapy, reviewing data from the most recently approved innovations in the field. Nicole Koulisis, MD, joins the program to review data on ocular injuries linked to social unrest in the summer of 2020. What were the causes linked to ocular injuries, how severely was vision affected, and what were final outcomes for these patients?

This editorially independent podcast is supported with advertising.

Matching Patients to Therapy in Wet AMD: How New Technology May Alleviate Treatment Burden Dec 14, 2021

In the first of this three-part series reviewing topics in wet AMD, Carl Regillo, MD, and Adrienne Scott, MD, join moderator John Kitchens, MD, to submit a pair of real-world patient cases illustrating how the need to reduce the burden of care may drive treatment decisions in patients with wet AMD. After they reveal how they managed their respective patient cases, Drs. Regillo and Scott join Dr. Kitchens for a review of how the latest innovations in retina could improve patients’ lives by alleviating treatment burden.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Medical Management of Macular Holes Dec 10, 2021

As more data are published regarding medical intervention for macular hole closure, retina specialists want to know which patients are best suited for this approach and in which cases it may be most effective. Christina Weng, MD, MBA, invites Brian Do, MD; Mrinali Gupta, MD; and Dimitra Skondra, MD, PhD, to summarize and respond to a pair of retrospective case series that explored the safety and efficacy of drop regimens for macular hole closure. The group discusses the papers’ findings and comments on their own experience with medical management of macular holes.

This editorially independent podcast is supported with advertising.

The Latest on Gene Therapy for Inherited Retinal Diseases Dec 07, 2021

In this roundtable moderated by Allen C. Ho, MD, IRD experts discuss their experiences treating patients with voretigene neparvovec (Luxturna, Spark), tips and tricks for subretinal delivery, and the nuances of genetic testing. Participants include Mark E. Pennesi, MD, PhD; Jacque L. Duncan, MD; Andreas Lauer, MD; Aaron Nagiel, MD, PhD; and Artur V. Cideciyan, PhD. To read the article, click here.

This podcast is editorially independent.

AAO 2021: PALADIN for DME and ROP Updates From the ICROP Dec 03, 2021

Extending treatment duration in patients with DME whose disease is responsive to steroid therapy could be instrumental in ensuring that visual disruption is kept at a minimum. How might the 3-year results from the PALADIN study guide treatment in the near future? Michael Singer, MD, reviewed data from a phase 4, 3-year, real-world study of patients whose DME was managed with fluocinolone acetonide 0.19 mg implant (Iluvien, Alimera Sciences). And NRR sat down with R.V. Paul Chan, MD, MSc, MBA, who summarized updates to ROP therapy as outlined in the 3rd edition of the International Classification of Retinopathy of Prematurity. What are the updates, and what spurred the ICROP to make them? Tune in to find out.

This editorially independent podcast is supported with advertising.

AAO 2021 Late Breakers: DAVIO and NORSE-2 Nov 30, 2021

Is a technology that inhibits tyrosine kinase and shows activity against all isoforms of VEGF and placental growth factor the future of wet AMD therapy? Data from the DAVIO study, which were shared at the 2021 AAO Annual meeting late-breakers session, could be of interest. David Boyer, MD, discussed the drug design of EYP-1901 (EyePoint Pharmaceuticals) and summarized the findings of the phase 1 DAVIO study, which examined the drug’s use in wet AMD patients. NRR also invited Firas Rahhal, MD, to review the safety and efficacy findings of the phase 3 NORSE-2 trial, which explored use of an ocular formation of bevacizumab (bevacizumab-vikg, Outlook Therapeutics) in patients with wet AMD.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Biosimilars in Wet AMD Nov 26, 2021

The biosimilars are coming—and studies about them are starting to fill the literature. One such study is the COLUMBUS-AMD study, which evaluated the clinical equivalence of FYB201 to ranibizumab for the treatment of wet AMD. Aleksandra Rachitskaya, MD, breaks down the study with Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD. The group expands on what biosimilars are and asks what the future of retina could look like if biosimilars are approved for clinical use.

This editorially independent podcast is supported with advertising.

AAO 2021: Protocol W and Monitoring for Wet AMD Nov 23, 2021

Can anti-VEGF agents act as effective prophylactic treatment for diabetic patients with a high risk of developing diabetic eye disease? Data from the Protocol W’s 2-year timepoint shared at the 2021 AAO Annual meeting might provide some answers on that question. Raj Maturi, MD, joined New Retina Radio to discuss his podium presentation on the topic.

New Retina Radio also invited Usha Chakravarthy, MD, PhD, to the program to outline her presentation on the secondary endpoints of the EDNA study. What was found when a team closely monitored patients for progression of unilateral to bilateral wet AMD? Join us on this episode to hear the details from these two presentations.

This editorially independent podcast is supported with advertising.

AAO 2021 Late Breakers: GATHER1 and ALTISSIMO Nov 19, 2021

Knowing at which point in the course of disease progression a drug for geographic atrophy could be most effective may be key to unlocking a treatment paradigm if a drug is approved. What late-breaking data presented at the 2021 AAO annual meeting could help inform retina’s eventual strategy to treat GA?

New Retina Radio spoke with David Lally, MD, about his presentation on a post hoc analysis of the GATHER1 study to learn more about how GA patients who received avacincaptad pegol (Zimura, IVERIC bio) progressed from nascent disease to more advanced disease.

We also heard from Veeral Sheth, MD, MBA, about the phase 2b ALTISSIMO study, which explored the use of GB-102 (Graybug Vision) for the treatment of wet AMD. Just how long might a drug administered only twice a year provide relief to wet AMD patients? Stay with us to find out.

This editorially independent podcast is supported with advertising.

Developing an innovative drug delivery system for nAMD Nov 16, 2021

The treatment landscape for nAMD has expanded to include a refillable, intraocular device that continuously delivers therapy. What was the inspiration behind this new treatment approach? John Kitchens, MD is joined by inventor Eugene de Juan, MD and physician-scientist Tony Adamis, MD to discuss the device and the innovative technology behind its development. During this podcast, they reflect on how their careers and contributions from others in the field led to the drug delivery system. This special episode of New Retina Radio is supported by Genentech USA, Inc., which is responsible for its content.

International Perspectives on ROP Nov 12, 2021

How do the latest data and treatment guidelines inform treatment strategies for retinopathy of prematurity (ROP) among European and Latin American retina specialists? Moderator Prof. Andreas Stahl (Germany) and panelist Dr. Maria Ana Martinez-Castellanos (Mexico) discuss the dynamics of patient care in their respective regions, and are joined by Silke Mader from the European Foundation for the Care of Newborn Infants to hear about the organization’s initiatives related to ROP.

This editorially independent podcast is supported with advertising.

Luminaries in Retina: Kirk Packo, MD, FACS (Part 2) Nov 09, 2021

In part 2 of this special podcast interview with John W. Kitchens, MD, and Kirk Packo, MD, FACS, they dive into Dr. Packo's involvement in the creation of AAO subspecialty day, his passion for honoring the history of retina, and his assistance in advocating for vitreoretinal surgery improvements.

This podcast is editorially independent.

Luminaries in Retina: Kirk Packo, MD, FACS (Part 1) Nov 09, 2021

In this new podcast episode, John W. Kitchens, MD, interviews Kirk Packo, MD, FACS, around his triumphant career and his decision to retire from practicing medicine following an unexpected diagnosis. In part 1 of 2, Dr. Packo describes his early career goals, his experience with residency matching, his background in acting and directing, and his passion for educating.

This podcast is editorially independent.

ASRS 2021: The Pipeline for Wet AMD and GA Nov 05, 2021

The pipeline in retina is bursting! Which datasets shared at the ASRS 2021 meeting provided insights into the future of retina? Mark Barakat, MD, joins the podcast to discuss topline results from a study examining the suprachoroidal delivery of RGX-314 (RegenxBio). And Nancy Holekamp, MD, stops by to educate us on the potential for targeting C1q in the complement cascade in patients with geographic atrophy. What’s the latest with the phase 2 ARCHER study? Find out on this episode.

This editorially independent podcast is supported with advertising.

ASRS 2021: Losing GA Patients to Follow-up and DME Meta-analysis Oct 29, 2021

The age of big data allows researchers to uncover how real-world patients with geographic atrophy (GA) behave. What did a deep dive into the IRIS Registry find? We spoke with Durga Borkar, MD, about her research team’s findings on which GA patients are most at risk to being lost to follow-up, which may inform treatment strategies once a drug is approved. And we sat down with M. Ali Khan, MD, whose meta-analysis of RISE/RIDE and three DRCR Retina Network studies explored possible visual outcomes gaps in Black and White patients with diabetic eye disease.

This editorially independent podcast is supported with advertising.

ASRS 2021: ARCHWAY and TENAYA/LUCERNE Oct 22, 2021

We may be on the cusp of the next great era of wet AMD therapy. Which phase 3 data will guide physician decision-making if new technologies are approved by regulatory bodies? Chirag Jhaveri, MD, spoke with New Retina Radio about anatomic data collected in the phase 3 ARCHWAY study. How did patients who received the Port Delivery System with Ranibizumab (PDS, Genentech) differ from those on monthly ranibizumab (Lucentis, Genentech) in terms of fluctuation in central subfield thickness? And as FDA weighs the possible approval of faricimab for the treatment of wet AMD, we hear from Karl Csaky, MD, PhD, about the safety, efficacy, and durability of the drug for wet AMD in the TENAYA and LUCERNE studies.

This editorially independent podcast is supported with advertising.

Vitreous Opacities: How ODs and MDs Can Collaborate Oct 19, 2021

How can retina surgeons work with optometrists to create a framework that best manages the cases of patients with vitreous opacities? To answer this question, John Kitchens, MD, turns to Tarek Hassan, MD, and Walt Whitley, OD, MBA. The panel discusses how collaboration can transition patients smoothly to surgical consultation, the anatomy of a referral, and if some patients are better suited for surgery than others.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Treating CMV with Adoptive Immunotherapy Oct 15, 2021

Cytomegalovirus (CMV) retinitis continues to challenge retina specialists. Could use of CMV-specific cytotoxic T lymphocytes be an effective strategy in some patients? And if so, in whom? To answer these questions, Christina Weng, MD, MBA, is joined by study author Mrinali Gupta, MD, and panelists Brian Do, MD, and Dimitra Skondra, MD, PhD. During their discussion, we hear about the structure and findings of the study and learn about how these new data may affect treatment algorithms for patients with newly diagnosed CMV retinitis.

This editorially independent podcast is supported with advertising.

International Perspectives: RVO Oct 08, 2021

In the next installment of the New Retina Radio miniseries "International Perspectives," moderator Jennifer Arnold (Australia) in joined by panelists Ramin Tadayoni (France) and Armin Wolf (Germany) to discuss the history and contemporary trends of RVO therapy.

This editorially independent podcast is supported with advertising.

Vitreous Opacities: Hearing from Anterior and Posterior Segment Surgeons Oct 01, 2021

It isn't often that anterior segment and posterior segment surgeons discuss surgery. New Retina Radio, in a crossover episode with CRST: The Podcast, is changing that by initiating a conversation about surgery for vitreous opacities. John Kitchens, MD, invites retina specialist Maria Berrocal, MD, and anterior segment surgeon Elizabeth Yeu, MD, to chat surgical pearls, patient management tactics, and whether premium IOLs are exacerbating vitreous opacities. Stick around at the end of the episode for some compelling conversation that our editors salvaged from the cutting room floor.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Exudative AMD in FILLY and GATHER1 Results Sep 17, 2021

As retina inches closer to a therapy that is safe and effective for the treatment of GA in the presence of dry AMD, the VBS Journal Club meets to review a pair of papers on a pair of pipeline treatments undergoing phase 3 evaluations. Aleksandra Rachitskaya, MD, is joined by Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD, to review phase 2/3 GATHER1 study, which is evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio). They also discuss a post hoc evaluation of the phase 2 FILLY study to determine which factors may be linked to the development of exudative AMD in some study patients after treatment with pegcetacoplan (Apellis), which is underdoing phase 3 investigation in the DERBY and OAKS studies.

This editorially independent podcast is supported with advertising.

The Art of Drug Choice: International Panel in Wet AMD: Safety Data Sep 10, 2021

Safety will ultimately drive decision-making for patients with wet AMD. What are the latest safety data in the MERLIN, ARCHWAY, OPTIC, RGX-314, and TENAYA/LUCERNE trials? Moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), sift through the latest safety data to determine how concerns about safety could shape the future of wet AMD therapy.

This editorially independent podcast is supported with advertising.

Vitreous Opacities: Innovations and the Decision to Operate Sep 03, 2021

Perspectives regarding surgery for vitreous opacities (VOs) have shifted in the past several years. How have innovations in surgical instrumentation, visualization, and IOL technology changed how surgeons approach VOs? John Kitchens, MD, sits down with S.K. Steven Houston III, MD, and Christina Weng, MD, MBA, to hear their perspectives on the modern state of VOs, learn about their surgical tactics, and establish how they determine when to send patients to surgery.

This editorially independent podcast is supported with advertising.

The Art of Drug Choice: International Panel in Wet AMD: The Pipeline Sep 01, 2021

The pipeline of wet AMD treatments is inspiring. What can retina specialists around the world expect when it comes to wet AMD therapy candidates KSI-301 (Kodiak Sciences), RGX-314 (RegenxBio), and ADVM-022 (Adverum Biotechnologies)? Join moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), as they review early-phase data from some of the possible wet AMD drugs of the future.

This editorially independent podcast is supported with advertising.

International Perspectives: DME Aug 27, 2021

In this opening installment of the New Retina Radio miniseries "International Perspectives," moderator Patricio Schlottmann (Argentina) sits down with panelists Catherine Creuzot-Garcher (France) and Adnan Tufail (United Kingdom) to review their strategies for treating patients with diabetic macular edema. The group discusses government regulations regarding the use of particular therapies and reviews why, in many cases, anti-VEGF therapy is the most effective therapeutic option.

This editorially independent podcast is supported with advertising.

The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to Watch Aug 20, 2021

If new treatment options for wet AMD are approved for treatment, retina specialists will have even more options to switch patients to a new therapy. Which drug candidates have phase 3 data and real-world data that could point toward upcoming action by regulatory bodies? Arshad M. Khanani, MD, MA (United States), convenes an international panel comprised of Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to review data related to brolucizumab (Beovu, Novartis), the Port Delivery System with Ranibizumab (Genentech), and faricimab (Roche).

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Data in the Wake of COVID-19 Aug 13, 2021

As the threat of COVID-19 subsides, scientists are working to make sense of the information that was gathered during the pandemic. Caroline Baumal, MD, asks M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, to tackle two papers that analyze data collected during this time. First, they address the strengths and limits of a paper from the infectious disease realm that used history of AMD as a marker for complement inhibition in patients with COVID-19. Then, they parse the details of an article reviewing how real-world high-frequency patients with wet AMD fared when treatment intervals were increased during the height of the pandemic.

This editorially independent podcast is supported with advertising.

The Art of Drug Choice: International Panel in Wet AMD: When and Why Switching Therapy Makes Sense Aug 06, 2021

Retina specialists around the world aim to reduce treatment burden while maximizing therapeutic outcomes in patients. How do global experts decide when to switch and to which therapy? Arshad M. Khanani, MD, MA (United States), is joined by Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to discuss tactics for moving wet AMD patients to new therapies or regimens. Also, Prof. Garweg shares a case of a patient who benefited from a new treatment option approved for wet AMD.

This editorially independent podcast is supported with advertising.

Surgical options for treating AMD: Clinical Implications and Impact Jul 29, 2021

In the third episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Carl Awh, MD, and Dante Pieramici, MD, about surgical options for neovascular AMD and how they might be applied in clinical practice. Although some of these options are still in the later stages of development, the panel looks forward to options that may truly change the treatment paradigm for the better. Click here to listen to this and other episodes in this series.

This editorially independent podcast is supported with advertising.

Advances in Gene Therapy for Wet AMD Jul 26, 2021

In this roundtable moderated by Allen C. Ho, MD, experts in gene therapy discuss the latest data, clinical trial hurdles, and the promise these programs hold for patients being treated for wet AMD. Participants include Robert L. Avery, MD; Peter Campochiaro, MD, PhD; Jeffrey S. Heier, MD; Szilárd Kiss, MD; and Charles Wykoff, MD, PhD.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Masking in Retina: Keeping Patients Safe from Bacterial Exposure Jul 16, 2021

Masks are effective in curbing transmission of COVID-19. But could they also direct bacteria toward the ocular region? Yoshi Yonekawa, MD, hears from two primary study investigators—Ajay Kuriyan, MD, and Jonathan Chang, MD—about their newly published studies, and invites Paula Pecen, MD, to evaluate the studies' designs, findings, and clinical relevance. After the break, all four doctors compare the two papers and review their respective masking protocols.

This editorially independent podcast is supported with advertising.

Reconsidering treatment endpoints in real-world clinical practice: is achieving a favorable retreatment interval a goal of therapy? Jul 09, 2021

In the second episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Jennifer Lim, MD, and Charlie Wykoff, MD, PhD, about the challenges inherent to finding the best retreatment interval for each patient. The panel also shares thoughts on how clinical trials could be structured to deliver data that would help clinicians understand durability of existing and new and novel treatment options. Click here to listen to this and other episodes in this series.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Autologous Retina Transplant for Macular Holes Jun 25, 2021

How effective is the use of autologous retina transplant for the treatment of macular holes? Caroline Baumal, MD, moderates a panel comprised of M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, during which they summarize and comment on a recent research paper on this subject published in the journal Ophthalmology. After the break, the group discusses which cases are best suited for this technique and discuss tactics for teaching fellows how to perform autologous retinal transplant.

This editorially independent podcast is supported with advertising.

Real-world impact of patients lost to follow-up: factors that drive nonadherence and strategies for encouraging better follow-up from patients Jun 11, 2021

In this episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Margaret Chang, MD, and David Eichenbaum, MD, about the consequences of missed injection appointments and less than ideal adherence to monitoring among patients with neovascular AMD. Listen in as the experts discuss some of the challenges inherent to treating patients in real-world practice and share insights on strategies for encouraging adherence.

This editorially independent podcast is supported with advertising.

ARVO 2021 Coverage: NGM621 and COOG2 Jun 04, 2021

C3 is a possible target in patients with geographic atrophy. What do the latest data from ARVO tell us about the safety and tolerability of NGM621, a drug aimed at that point in the complement cascade? David Eichenbaum, MD, sat down with New Retina Radio to review the results of a phase 1 study evaluating NGM621 in patients with geographic atrophy.

Also, Amy Schefler, MD joined the show to review the design, methods, and rationale for the creation of the COOG2, or the second iteration of the Collaborative Ocular Oncology Group. How might the COOG help advance treatment for ocular cancer?

This editorially independent podcast is supported with advertising.

ARVO 2021: GATHER1 Study and CME After RRD Surgery May 28, 2021

18-month results for GATHER1 look promising, but another pivotal study is still in the works. What else needs to happen for Zimura to become the first FDA-approved therapy for geographic atrophy? New Retina Radio spoke with Veeral Sheth, MD, about what he shared regarding the GATHER1 study at this year’s ARVO meeting.

We also spoke with Matthew Starr, MD, about his research on the development of CME following rhegmatogenous retinal detachment surgery. Could his findings help surgeons better understand the risk factors for complication after surgery?

This editorially independent podcast is supported with advertising.

ARVO 2021 Coverage: TENAYA/LUCERNE Results—and Is Fluid OK in Wet AMD? May 21, 2021

The phase 3 TENAYA and LUCERNE trials, which assessed the safety and efficacy of faricimab for wet AMD therapy, have wrapped up. What did the researchers learn? New Retina Radio spoke with Arshad Khanani, MD, MA, about his ARVO presentation on these trials. We also spoke with David Lally, MD, whose ARVO presentation adds new data to the great fluid debates in wet AMD. What did his research team uncover that can inform our understanding of fluid dynamics in these patients?

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Protocol W: How Might the Data Change Practice? May 14, 2021

Need a refresher on Protocol W, the latest study from the DRCR Retina Network? Yoshi Yonekawa, MD, invites VBS members Ajay Kuriyan, MD; Anton Orlin, MD; and Paula Pecen, MD, to review the data from Protocol W and to discuss how the study may change their practice patterns.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: PRO Study Group Papers: Part 2 Apr 15, 2021

In the second part of this two-part series on literature in retinal detachment surgery, moderator Jay Sridhar, MD, is joined by panelists Brian Do, MD; Sabin Dang, MD; and Avni Finn, MD, MBA, to discuss a pair of recently published reports. The panel reviews an article on the outcomes of primary RRD repair with extensive scleral-depressed vitreous and dynamic examination, as well as a report on 360º laser retinopexy during primary vitrectomy with or without scleral buckling for RRD.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: PRO Study Group Papers: Part 1 Mar 30, 2021

In the first part of this two-part series reviewing reports from the Primary Retinal Detachment Outcomes Study Group, moderator Jay Sridhar, MD, invites panelists Brian Do, MD; Sabin Dang, MD; and Avni Finn, MD, MBA, to dissect a trio of papers. They discuss the results of studies examining retinal detachment surgery outcomes in phakic and pseudophakic patients. After the break, the panel summarizes and reviews the findings from a report comparing vitrectomy alone to vitrectomy with scleral buckle for retinal detachment with inferior retinal breaks.

This editorially independent podcast is supported with advertising.

Angiogenesis 2021: Early Phase Data Mar 23, 2021

Early phase data sets are one of the stars of the Angiogenesis, Exudation, and Degeneration annual meeting. Which presentations are worth a second look? John Kitchens, MD, is joined by Nadia Waheed, MD, and Charles Wykoff, MD, PhD, as they share data from their respective presentations showcased at this year’s meeting. After the break, Drs. Kitchens, Waheed, and Wykoff chat what these early phase data could mean for the future of retina care.

This editorially independent podcast is supported with advertising.

Angiogenesis 2021: Wet AMD Mar 12, 2021

Which upcoming therapies will extend duration for patients with wet AMD? John Kitchens, MD, sits down with Diana Do, MD, and Carl Regillo, MD, to hear about their presentations at this year’s Angiogenesis, Exudation, and Degeneration annual meeting. After the break, Drs. Kitchens, Do, and Regillo discuss how the future of wet AMD therapies may alter clinical care for patients undergoing treatment.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: OCT Biomarkers in New Onset GA Mar 08, 2021

Can OCT be used to detect areas at risk for GA progression in patients with intermediate AMD? Yoshihiro Yonekawa, MD, invites Marion Munk, MD, PhD; Lejla Vajzovic, MD; and David Xu, MD, to discuss a paper published by the AREDS2 Group on this topic. They explore the researchers' findings and discuss the clinical implications of the study's results.

This editorially independent podcast is supported with advertising.

Angiogenesis 2021: Geographic Atrophy Mar 04, 2021

How close are retina specialists to offering an effective therapy for patients with geographic atrophy secondary to dry AMD? John Kitchens, MD, hears summaries of two talks from Pravin Dugel, MD, and SriniVas Sadda, MD, from this year’s Angiogenesis, Exudation, and Degeneration meeting. After the break, Dr. Kitchens moderates a discussion about the nuances of bringing treatments in this disease to patients.

This editorially independent podcast is supported with advertising.

Let’s Talk Diversity and Inclusion Mar 01, 2021

In this roundtable hosted by María H. Berrocal, MD, and Audina M. Berrocal, MD, new department chairs in retina share their journeys to leadership and how to move the needle on diversity in the field. Participants include Sophie J. Bakri, MD, MBA; R.V. Paul Chan, MD, MSc, MBA, FACS; and Shlomit Schaal, MD, PhD, MHCM.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Anti-VEGF vs Surgery + PRP for VH with PDR Feb 25, 2021

Aleksandra Rachitskaya, MD, moderates a panel comprised of Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD, to review a study from the DRCR Retina Network that compared intravitreal aflibercept (Eylea, Regeneron) to vitrectomy with panretinal photocoagulation for the treatment of vitreous hemorrhage secondary to proliferative diabetic retinopathy. The group summarizes the study and weighs how its findings could affect clinical practice.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Phase 2 LADDER Study Data Feb 10, 2021

Aleksandra Rachitskaya, MD, leads a discussion with Mrinali Gupta, MD; Eric Nudleman, MD, PhD; and Aris Thanos, MD, about the phase 2 LADDER study, which evaluated the Port Delivery System With Ranibizumab (Genentech) in patients with wet AMD. Listen to a summary of the study and a thorough discussion of its implications with this group of Vit-Buckle Society members.

This editorially independent podcast is supported with advertising.

International Perspectives: Digital Solutions for the Management of Amblyopia Feb 08, 2021

In this podcast, Prof. Richard Harrad (UK) joins Prof. Ben Thompson (Canada) and Prof. Ann Webber (Australia) for a discussion on the use of dichoptic therapy in the management of amblyopia. In this episode, we consider the limitations of the current clinical approach to amblyopia before discussing dichoptic therapy, a new and innovative technology with the potential to address some of the unmet needs in the management of this common condition. The faculty review the available evidence for dichoptic therapy, its potential benefits, the challenges associated with its use and how these might be overcome.

This editorially independent podcast is supported with advertising.

International Perspectives: How Will Artificial Intelligence Affect the Practice of Ophthalmology? Jan 28, 2021

In this podcast, Dr Peter Kaiser (USA) leads a conversation with Prof. James Wolffsohn (UK) and Dr Pearce Keane (UK) in which they explore the use of AI technology in clinical practice and how it may lead to changes in the management of patients. Considering both the front and the back of the eye, the faculty discuss current and potential future uses of AI in ophthalmology and optometry, the challenges associated with the development and integration of AI systems, and the benefits that may result from its use in eye care.

This editorially independent podcast is supported with advertising.

Clinical Impacts From AAO 2020: Drs. Singh, Ehlers, and Gillies Jan 25, 2021

Will data shared at AAO 2020 affect your clinical decision-making with wet AMD patients? Rishi Singh, MD, invites Justis Ehlers, MD, and Mark Gillies, MD, PhD, to review their presentations from AAO 2020 and discuss how clinical practice may be affected by their new information. Dr. Ehlers presented data on fluid volatility and the software used to measure it, and Dr. Gillies examined a 10-year data set of real-world wet AMD patients.

This editorially independent podcast is supported with advertising.

Fluid in Neovascular Age-Related Macular Degeneration – Evolution of Understanding Jan 20, 2021

Join Dr. Rishi Singh (USA) as he speaks with Prof. Jennifer Arnold (Australia), Prof. Mark Gillies (Australia) and Dr. SriniVas Sadda (USA) about the role and importance of fluid in the management of retinal diseases. In this episode, we will look at the different fluid compartments and our current understanding of their relevance to neovascular AMD. We will discuss the learnings gained from the HARBOR and FLUID clinical trials and the Fight Retinal Blindness! project, and consider key questions such as whether fluid can be protective and which types of fluid need to be treated aggressively.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Imaging Modalities in DR Jan 08, 2021

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, review real-world data that compare widefield swept-source OCT angiography with ultra-widefield color fundus photography and fluorescein angiography for the detection disease activity in patients with diabetic retinopathy.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Intravitreal Dexamethasone Implant in DME Patients Dec 21, 2020

Host Jorge Fortun, MD, and guests Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, discuss a retrospective study on the efficacy and safety of an intravitreal dexamethasone implant (Ozurdex, Allergan) in patients with diabetic macular edema. They review the top-line data and study design of this real-world report.

This editorially independent podcast is supported with advertising.

Clinical Impacts From AAO 2020: Drs. Singh, Do, and Heier Dec 17, 2020

How will data shared at AAO 2020 impact clinical decision-making in wet AMD therapy? Rishi Singh, MD, is joined by Diana Do, MD, and Jeffrey Heier, MD, to review their talks from the AAO 2020 meeting and to see how their data might influence the day-to-day work of clinicians in retina. Dr. Do presented a meta-analysis comparing all anti-VEGF agents and regimens for the treatment of wet AMD, and Dr. Heier examined baseline patient characteristics in HAWK/HARRIER to have a better understanding of IOI events.

This editorially independent podcast is supported with advertising.

DRCR Retina Network Protocol AB at AAO Dec 07, 2020

DRCR Retina Network Protocol AB compared aflibercept (Eylea, Regeneron) to PPV and PRP in patients with diabetic vitreous hemorrhage. DRCR Retina Network Vice Chair and Protocol AB chair Andrew Antoszyk, MD, joins NRR to review the study’s findings, which were presented at this year’s AAO Annual Meeting.

This editorially independent podcast is supported with advertising.

AAO Late Breaker: IRIS Registry Data on GA Dec 02, 2020

Tracking real-world data on geographic atrophy has been patchwork process—until now. Thanks to the AAO IRIS Registry, real-world information on eye diseases can be gathered and assessed. What was found in the IRIS Registry regarding GA, and how will it change the way you practice? Ehsan Rahimy, MD, outlines how he and his team identified patients and trends, and summarizes how he applied the group’s findings to his practice. Dr. Rahimy presented data from this discussion during this year’s AAO Annual Meeting Late Breakers session.

This editorially independent podcast is supported with advertising.

Coding Changes for 2021 at AAO Nov 30, 2020

In 2021, E/M codes will undergo their most significant changes since 1997. How will these changes affect your billing and coding—and what processes can you put in place to get ahead of the game? AAO Coding and Practice Management Executive Joy Woodke informs us of the changes ahead, which were shared at this year’s AAO Annual Meeting.

This editorially independent podcast is supported with advertising.

AAO Late Breaker: Ang-2 Mediation in DME Therapy Nov 25, 2020

The next generation of therapy for DME patients will require looking beyond the VEGF pathway. In the phase 2 BOULEVARD study, researchers are assessing the safety and efficacy of the angiopoietin-2 mediator faricimab (Roche/Genentech) for the treatment of DME. Could the angiopoietin pathway present a new option for patients? Karl Csaky, MD, PhD, sits down with NRR to review data from the study, which were shared at this year’s AAO Annual Meeting Late Breakers session.

This editorially independent podcast is supported with advertising.

Retinal Arteriolar Macroaneurysm and Anti-VEGF Therapy at AAO Nov 23, 2020

Retinal arteriolar macroaneurysm (RAM) usually regresses spontaneously, but can lead to irreversible vision loss if regression does not occur. Could anti-VEGF therapy be an option for these patients? J. Fernando Arevalo, MD, PhD, joins NRR to discuss data from a study that asked that question. He presented the data at this year’s AAO Annual Meeting.

This editorially independent podcast is supported with advertising.

AAO Late Breaker: KSI-301 in DME Therapy Nov 20, 2020

The burden of anti-VEGF therapy is particularly high in DME patients, many of whom are young, in the workforce, and unable to easily maintain monthly therapy. Could the antibody biopolymer conjugate KSI-301 (Kodiak Sciences) alleviate that burden while maintaining the outcomes experienced with anti-VEGF therapy? Arshad M. Khanani, MD, MA, shares the results of the phase 1B, long-term, multidose study that was presented at this year’s AAO Annual Meeting Late Breakers session.

This editorially independent podcast is supported with advertising.

The Art of Drug Choice: Safety in Wet AMD Nov 19, 2020

NRR’s miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” wraps up with moderator Dr. Khanani and panelists Drs. Fuller, London, and Weng discussing safety data. How have safety considerations changed in the wet AMD treatment landscape, and how do clinicians balance the risks and rewards of switching to a new agent? Additionally, Dr. Khanani closes out the series with the case of a patient whose disease stopped responding after a decade of anti-VEGF therapy. Listen here to learn how he approached the case.

This editorially independent podcast is supported with advertising.

The Art of Drug Choice: Wet AMD Pipeline Nov 19, 2020

This NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data” continues as Dr. Khanani and the roundtable participants Drs. Fuller, London, and Weng review the wet AMD pipeline with a focus on anti-Ang-2 therapy (faricimab, Roche/Genentech) and gene therapy (RGX-314, RegenxBio and ADVM-022, Adverum Biotechnologies). After the break, Dr. London shares the case of a patient with wet AMD who experienced a ceiling of response to anti-VEGF therapy. Did a switch to brolucizumab (Beovu, Novartis) result a change?

This editorially independent podcast is supported with advertising.

The Art of Drug Choice: Wet AMD and the Latest Data [Miniseries] Nov 19, 2020

Arshad M. Khanani, MD, MA, leads a roundtable consisting of Christopher G. Fuller, MD; Nikolas J.S. London, MD, FACS; and Christina Y. Weng, MD, MBA, as they discuss the art of drug choice in wet AMD therapy. The panel discusses how and why they switch therapy in challenging wet AMD cases and reviews how the COVID-19 pandemic has factored into their treatment algorithms. Also, Dr. Fuller shares the case of a wet AMD patient whose waning response to traditional therapy required intervention with an intravitreal dexamethasone implant (Ozurdex, Allergan).

This editorially independent podcast is supported with advertising.

The Art of Drug Choice: Phase 3 Trials in Wet AMD Nov 19, 2020

In episode 2 of the NRR miniseries “The Art of Drug Choice: Wet AMD and the Latest Data,” Dr. Khanani and roundtable participants Drs. Fuller, London, and Weng review the latest phase 3 efficacy data from the HAWK/HARRIER, ARCHWAY, and CEDAR/SEQUOIA studies. Also, Dr. Weng shares the case of a wet AMD patient whose response to therapy and toleration of treatment burden mandated a change in treatment. Could brolucizumab (Beovu, Novartis) be a solution?

This editorially independent podcast is supported with advertising.

ARCHWAY at AAO Nov 18, 2020

The Port Delivery System With Ranibizumab (Genentech) is under investigation for the treatment of wet AMD in the phase 3 ARCHWAY trial, data from which was shared at this year’s AAO Annual Meeting. Nancy Holekamp, MD, sits down with NRR to provide a primary analysis of the results of ARCHWAY and discusses safety outcomes.

This editorially independent podcast is supported with advertising.

New Retina Radio Journal Club: Putting the Fun Back in Journal Club Nov 10, 2020

New Retina Radio’s John Kitchens, MD, and Jorge Fortun, MD, introduce the premier episode of New Retina Radio Journal Club, a new series dedicated to reviewing the latest papers and how they relate to day to day clinical practice. In this episode, Dr. Fortun is joined by Cynthia Qian, MD; Christina Weng, MD, MBA; and Basil Williams, MD, to discuss two papers that address the role, or lack thereof, of anti-VEGF therapy in the treatment of neovascular age-related macular degeneration and geographic atrophy.

This editorially independent podcast is supported with advertising.

Clinical considerations for optimal management of patients with IRDs Oct 30, 2020

In this podcast, Prof. Bart Leroy (Belgium), Prof. Isabelle Audo (France) and Prof. Robert Maclaren (UK) discuss the management of patients with inherited retinal diseases (IRDs), from the initial identification of a patient with an IRD and referral to specialist center, through to the confirmation of a diagnosis using genotyping and the long-term implications for the patient of receiving that diagnosis. They discuss the current treatment landscape for patients with IRDs and outline future potential therapies on the horizon.

This editorially independent podcast is supported with advertising.

[Back to Practice] Combating Patient Misinformation Regarding COVID-19 Oct 16, 2020

Arming patients with knowledge is key to fighting any disease. What happens when a confluence of factors create a breeding ground for an uneducated patient population? John W. Kitchens, MD (United States), is joined by Patricio Schlottmann, MD (Argentina), Nicole Eter, MD (Germany), and Adnan Tufail, MBBS, MD, FRCOphth (United Kingdom) to review tactics for educating patients and battling misinformation in the COVID-19 era.

This editorially independent podcast is supported with advertising.

[Back to Practice] Telemedicine & Combating Patient Misinformation Oct 15, 2020

The COVID-19 pandemic accelerated the use of telemedicine. How has this held up in retina now that we’ve had more than 6 months of experience under our belts? New Retina Radio host John Kitchens, MD, invites Judy E. Kim, MD; Byron Ladd, MD; and Carl D. Regillo, MD, to review how their practices have used (or not used) telemedicine during the pandemic. Also, Dr. Kitchens asks the panel how they’ve handled educating patients about the pandemic—and how they’ve tackled questions of misinformation.

This editorially independent podcast is supported with advertising.

[Back to Practice] Telemedicine in the COVID-19 Era Oct 03, 2020

Telemedicine has been put to the test during the COVID-19 pandemic. How is it holding up—and just how effective will it be going forward? John W. Kitchens, MD (United States), is joined by Francesco Boscia, MD (Italy); David Steel, MBBS, FRCOphth (United Kingdom); and Ramin Tadayoni, MD, PhD (France), to discuss how much telemedicine has delivered as promised.

This editorially independent podcast is supported with advertising.

[Back to Practice] Academic Settings in a Pandemic: Rules and Regulations Oct 01, 2020

The internal regulations governing academic institutions were tested during the COVID-19 surges of spring and summer. As we move into autumn, how effective have they been—and are any worth revisiting? New Retina Radio host John Kitchens, MD, reviews this topic with Dilraj Grewal, MD, from the Duke Eye Center; Adrienne Scott, MD, from the Wilmer Eye Institute; and Elliott Sohn, MD, from University of Iowa to gain a better understanding of how institutional safeguards kept patients and staff safe, and how they may have served as (sometimes necessary) roadblocks to getting practice back to pre-pandemic levels.

This editorially independent podcast is supported with advertising.

[Back to Practice] Educating the Next Generation of Surgeons During COVID-19 Sep 16, 2020

The disruptions to clinical and surgical workflows during the COVID-19 crisis are obvious. Less apparent are the downstream effects of adjustments to educational experiences. New Retina Radio host John Kitchens, MD, invites three leaders in academic retina—Sophie Bakri, MD, of the Mayo Clinic; Julia Haller, MD, of Wills Eye Hospital; and R.V. Paul Chan, MD, MSc, MBA, of the University of Illinois at Chicago—to discuss how training and selection of fellows has been altered during the COVID-19 pandemic, and to review the tactics their institutions have employed to mitigate the interference their programs have endured.

This editorially independent podcast is supported with advertising.

jCell Therapy for Retinitis Pigmentosa and Phase 2B Data Aug 31, 2020

Approaches to treating retinitis pigmentosa have included prosthetic devices and gene therapy. What if there was an approach that could treat the nearly 2 million worldwide patients with disease? Anthony Joseph, MD, discusses jCell technology, which may work independently of a patient’s genetic subtype to promote photoreceptor survival in retinitis pigmentosa patients. What data from a phase 2b trial were used to evaluate the efficacy of jCell technology? How will the therapy be tested going forward? What safety concerns should clinicians be aware of? Dr. Joseph has some answers.

This editorially independent podcast is supported with advertising.

[Back to Practice] What Happens During a COVID-19 Resurgence? Aug 28, 2020

A COVID-19 resurgence seems increasingly likely as autumn and winter approach the United States, forcing people indoors and increasing transmission risk. What can retina clinicians learn from the spring and summers waves of COVID-19 infections that could be applied to the cooler months of 2020? John W. Kitchens, MD, invites Steve Charles, MD; Amy Schefler, MD; and Jayanth Sridhar, MD, to gameplan the future of retina clinics.

This editorially independent podcast is supported with advertising.

[Back to Practice] Technology and COVID-19: Necessity Is the Mother of Invention Aug 26, 2020

Retina’s ability to adjust to a new environment should be commended. Which of the technologies introduced during the COVID-19 era are stopgaps and which will be a permanent part of the treatment landscape? John W. Kitchens, MD (United States), is joined by María H. Berrocal, MD (United States); Jean-Francois Korobelnik, MD, PhD (France); and Manish Nagpal, MBBS, MS, FRCS (Edin) (India), to forecast the future of retina’s technologic milieu.

This editorially independent podcast is supported with advertising.

Treat-and-Extend in the Real World Aug 21, 2020

Treat-and-extend therapy is a common tactic employed by retina specialists for treating wet AMD patients. What new data will grow the body of information retina specialists already draw on when making decisions about treatment regimen? Michael Singer, MD, shares details from a retrospective review of patient data over a 2-year period during which treat-and-extend regimens were employed.

This editorially independent podcast is supported with advertising.

Opioid Prescribing Patterns Among Retina Specialists Aug 12, 2020

In the midst of the COVID-19 pandemic, medicine cannot forget about the raging opioid epidemic taking place in the United States. What role to retina specialists play in fueling the opioid crisis, and how has their behavior changed for the better over time? Yoshihiro Yonekawa, MD, shares his research about opioid prescribing rates among retina specialists, tracing the field’s behavior over time, and offering a window into the specialty’s role in the crisis.

This editorially independent podcast is supported with advertising.

Continuous Dosing in LADDER Aug 04, 2020

The phase 2 LADDER study showed the Port Delivery System for ranibizumab was worthy of a phase 3 trial. Was the device able to deliver a continuous dose of therapy that was similar to what you’d find in monthly injection patients? Dilsher Dhoot, MD, reviews the pharmacokinetic data that researchers used to determine the rate of drug release and therapeutic benefit and previews the phase 3 ARCHWAY trial.

This editorially independent podcast is supported with advertising.

[Back to Practice] COVID-19 Clinical and Surgical Protocols: Which Changes Are Here to Stay? Aug 03, 2020

Protocols for clinical and surgical settings have been altered in the COVID-19 era. Which of those protocols are temporary, and which protocols will be a permanent part of practice? To answer this question, New Retina Radio host John W. Kitchens, MD, invites María Ana Castellanos-Martinez, MD (Mexico) and Matteo Forlini, MD (Italy) for a roundtable discussion on the future of retina care in the wake of COVID-19–related changes.

This editorially independent podcast is supported with advertising.

[Back to Practice] Education as In-Person Meetings Are Paused Jul 30, 2020

Conferences are an essential dynamic to the retina ecosystem that have been disrupted during the COVID-19 crisis. How will the field advance without in-person meetings? New Retina Radio host John W. Kitchens, MD, invites EURETINA General Secretary Anat Loewenstein, MD, and ASRS President Timothy G. Murray, MD, MBA, to discuss the future of in-person education, the evolving dynamics of physician-industry collaboration, and the solutions that retina societies have relied on to maintain retina’s camaraderie.

This editorially independent podcast is supported with advertising.

Faricimab in Phase 2 and 3 Jun 30, 2020

Safe and effective long-duration therapy in wet AMD treatment could be the solution to increasing patient adherence. Are we on the brink of a major breakthrough? Carl Danzig, MD, reviews the phase 2 STAIRWAY study, which evaluated the safety and efficacy of faricimab (Genentech/Roche) for the treatment of wet AMD, and previews the coming phase 3 trials TENAYA and LUCERNE.

This editorially independent podcast is supported with advertising.

Anti-VEGF, A Biography: Part 3 Jun 15, 2018

This story started in the early days of VEGF's isolation in the 1970s and brought us to the discovery of ranibizumab and bevacizumab in the mid 2000s. The data revealed at the ASRS meeting in 2005 would change retina forever-and usher in a new competitor with a chance to disrupt the landscape yet again.

Don't miss the final episode of this fascinating and important story told by those that lived it. We're bringing back some of the voices you've heard before, and some new ones, too. John D. Pitcher III, MD, invites Bob Avery, MD; David Brown, MD; Jeffrey Heier, MD; Nancy Holekamp, MD; Kirk Packo, MD; Phillip Rosenfeld, MD, PhD; and Bob Vitti, MD, to tell the latest chapter of anti-VEGF's biography.

This editorially independent podcast is supported with advertising.

Anti-VEGF, A Biography: Part 2 Nov 22, 2017

New Retina Radio continues its biography of anti-VEGF. John D. Pitcher III, MD, picks up the story where we left off: in a world where pegaptanib was the only intravitreal injection approved for treating wet AMD. But a deep dive into the literature and a few calculations on the back of a napkin are about to change retina practice forever. Guests in this episode include Bob Avery, MD; Dave Brown, MD; Anne Fung, MD; Jeffrey Heier, MD; Andrew Moshfeghi, MD, MBA; Kirk Packo, MD; and Philip Rosenfeld, MD, PhD. This editorially independent podcast is supported with advertising.

Beyond the Walls of ORs and Borders of Nations Aug 28, 2017

Practicing retina in the developing world means facing frustrating, unexpected, and sometimes dangerous circumstances. Don D'Amico, MD, R.V. Paul Chan, MD, and Pravin Dugel, MD, share their stories of engaging medical communities from Tanzania to Armenia and Vietnam to Nepal. This podcast is editorially independent.

Retina Is for the Birds Jun 14, 2017

Hawks have more than one fovea and a cornea that changes shape to sharpen focus on prey. Who knew? Well, one retina doctor did. James C. Major Jr, MD, PhD, joins us for an episode to review his early contributions to animal imaging. But the story is bigger than that. Dr. Major's journey illustrates that a marriage between two passions-in his case, the blossoming world of optical coherence tomography in the early 2000s and an ornithological hobby-can send a retina doctor down uncharted paths of scientific discovery. This podcast is editorially independent.

Anti-VEGF, A Biography: Part 1 Apr 24, 2017

Many young retina specialists have always known retina as an anti-VEGF world. But how did this happen? John D. Pitcher III, MD, joins Scott and Ranna in studio to deliver the first part of the tale of anti-VEGF in retina, taking the story back to the 1970s to tell the story of the discovery of VEGF, the creation of pegaptanib, and the struggles that early anti-VEGF encountered in retina. There are a lot of guests for this one, but the major players for this episode are Tony Adamis, MD; Bob Avery, MD; Jeff Heier, MD; and Kirk Packo, MD. This editorially independent podcast is supported with advertising.

Alphabet Soup: PhD, MBA, JD, MS Feb 24, 2017

All retina specialists have an MD; not all retina specialists have another postgraduate degree. In this episode of New Retina Radio, we examine how and why those degrees were obtained by retina specialists-and if they were even worth the time. Featuring Derek Kunimoto, MD, JD; Paul Hahn, MD, PhD; David Almeida, MD, PhD, MBA; and Scott Walter, MD, MS. This podcast is editorially independent.

The Dating Game Jan 23, 2017

Finding a partner for your retina practice can be a lot like dating-you need to find someone whose values align with your values, who enhances your best qualities, and who doesn't make you pull your hair out. In this episode, New Retina Radio goes retro-think The Dating Game but (slightly) less corny. Featuring Geeta Lalwani, MD, and Charlie Mango, MD. This podcast is editorially independent.

Je Ne Sais Quoi Dec 28, 2016

Last episode, we heard from women at various stages in their careers about the unique nature of practicing retina as a woman. In part 2 of 2, they discuss the role of men in the development of women, the merits of joining groups like Women in Retina, and how experience shapes perception of how the industry treats female candidates. Featuring Julia Haller, MD; Anat Loewenstein, MD; Geeta Lalwani, MD; Jessica Randolph, MD; and Talisa de Carlo, MD. This podcast is editorially independent.

Ophthalmologist Barbie Nov 16, 2016

Practicing retina consumes your life. Add a pair of X chromosomes into the mix, and you face a very different set of circumstances. In the debut episode of New Retina Radio, we sit down with Julia Haller, MD; Anat Loewenstein, MD; Jessica Randolph, MD; and Talisa de Carlo, MD, to hear about the how women in retina operate-and how men factor into the equation. This podcast is editorially independent.

Our TOPPODCAST Picks

Follow Us

Stay Connected

New Retina Radio by Eyetube

Related Podcasts

Links

Stay Connected